Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Cibinqo (abrocitinib by Quarter
Cibinqo (abrocitinib — atopic dermatitis) — U.S. reported YoY (%) (%)
Pfizer Cibinqo (abrocitinib: 39.0% in Q2 2026, down 20.0 pts from a year earlier.
Latest, Q2 2026
39.0%
Period ended Jun 28, 2026
Change on a year earlier
-20.0 pts
59.0% in Q2 2025
History
8 quarters
Since Q2 2024
Sources
8
Documents cited below
Where the Q2 2026 figure comes from
“|| Cibinqo | 94 | 69 | 38% | 34% | 34 | 24 | 39% | 61 | 44 | 37% | 32%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cibinqo (abrocitinib — atopic dermatitis) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 39.0% | -20.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 16.0% | +14.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 28.0% | -19.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 28, 2025 | 34.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 59.0% | +13.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 2.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 47.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 46.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗ |
Cite this data
StockData. (2026). Pfizer Cibinqo (abrocitinib (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/cibinqo-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.